Acceleron Pharma Outlines Corporate Objectives for 2015

Acceleron Pharma Outlines Corporate Objectives for 2015

January 12, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a biopharmaceutical company focused on the discovery, development and commercialization of novel protein therapeutics for cancer and rare diseases, today announced its major corporate research and development objectives for 2015. Acceleron has four internally discovered and developed investigational protein therapeutics in human clinical trials and expects all four molecules to be in either phase 2 or phase 3 clinical trials by the end of 2015.

T2 Biosystems to Present at the 33rd Annual J.P. Morgan Healthcare Conference

T2 Biosystems to Present at the 33rd Annual J.P. Morgan Healthcare Conference

January 8, 2015

Company Presentation at 11 a.m. PT January 15, 2015

LEXINGTON, Mass., Jan. 8, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO) today announced that John McDonough, president and chief executive officer, is scheduled to present at the 33rd annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2015, at 11 a.m. PT at the Westin St. Francis in San Francisco.

BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview

BIND Therapeutics Provides Clinical Update for BIND-014 and 2015 Strategic Overview

January 7, 2015

 - Enrolled first NSCLC patient with KRAS mutation in phase 2 KRAS mutant or squamous histology NSCLC trial based on encouraging clinical activity from ongoing phase 2 trial with goal of rapid advancement to pivotal studies -

Blend Therapeutics Appoints Distinguished Physician Scientist, Dennis Ausiello, MD, to Board of Directors

Blend Therapeutics Appoints Distinguished Physician Scientist, Dennis Ausiello, MD, to Board of Directors

January 7, 2015

WATERTOWN, MA – January 7, 2015 – Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has appointed Dennis A. Ausiello, MD, to the company’s Board of Directors. With deep experience and a distinguished record of leadership and accomplishment in medicine and scientific research, Dr. Ausiello brings a seasoned and unique perspective to support Blend’s continued growth and advancement as an innovative oncology drug developer.

Moderna Launches New Venture Valera LLC for Infectious Diseases

Moderna Launches New Venture Valera LLC for Infectious Diseases

January 8, 2015

Moderna venture to advance mRNA vaccines and mRNA-based passive immunity therapies

CAMBRIDGE, Mass., Jan. 8, 2015— Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™, today announced the launch of Valera LLC, a new Moderna venture focused exclusively on the advancement of vaccines and therapeutics for the prevention and treatment of viral, bacterial and parasitic infectious diseases. 

Syros Pharmaceuticals to Present at the 33rd Annual J.P. Morgan 2015 Healthcare Conference

Syros Pharmaceuticals to Present at the 33rd Annual J.P. Morgan 2015 Healthcare Conference

January 7, 2015

Syros Pharmaceuticals, a therapeutics company focused on discovering and developing novel gene control therapies, will present a corporate overview at the 33rd Annual J.P. Morgan Healthcare Conference, which takes place January 12 to 15, 2015, at the Westin St.

Symbiota Names Entrepreneurial Leader David P. Perry as President and CEO

Symbiota Names Entrepreneurial Leader David P. Perry as President and CEO

January 7, 2015

CAMBRIDGE, Mass., Jan. 7, 2015 /PRNewswire/ -- Symbiota™ announced today that David P. Perry has been named President and CEO to lead the company in its next phase of growth and commercialization. Symbiota is a pioneer of plant microbiome solutions that naturally promote crop health and improve agricultural production.

Onkaido Announces Appointment of Michael J. Morin, Ph.D., as Chief Scientific Officer

Onkaido Announces Appointment of Michael J. Morin, Ph.D., as Chief Scientific Officer

January 7, 2015

Former Pfizer research executive to lead scientific efforts in oncology drug development leveraging Moderna’s messenger RNA Therapeutics™ platform

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics

Blend Therapeutics Secures $21 Million Financing and Unveils Novel Pentarin™ Platform for Cancer Therapeutics

January 7, 2015

WATERTOWN, Mass.--(BUSINESS WIRE)--Blend Therapeutics, Inc., a biopharmaceutical company discovering new classes of medicines to treat cancer, announced today that it has secured $21 million in new funding. The new financing includes additional equity investment from a new investor and all of Blend’s existing venture investors in an expansion of the Series B round, as well as debt financing from an institutional investment firm.

Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12

Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12

January 5, 2015

CAMBRIDGE, Mass.Jan.